ONConcept® has successfully completed the pivotal BE study for Pomalidomide

ONConcept June 2023

We are excited to share that ONConcept® has successfully completed the pivotal BE study for Pomalidomide against the EU reference product 4 mg (Imnovid). This is a great achievement and yet another milestone in our journey. The ONConcept team is now focused on preparing the dossier for EU submission this August.

ONConcept® is the result of a powerful strategic collaboration in the field of oncology. This partnership brings together three independent, certified European pharmaceutical companies - Bluepharma, HELM AG, and WELDING GmbH & Co. KG.

The goal of this union is to create a leading partnership for complex, differentiated, and high potency products. The combined expertise and experience of these companies will enable them to deliver innovative treatments and technologies made in the EU to patients in need.


Bluepharma opens an industrial unit unique in Portugal and one of the largest in Europe

ONConcept March 2023

Bluepharma, a Portuguese pharmaceutical company, has just opened a state-of-the-art industrial unit specialized in the production of oral solid high potent drugs, namely in the oncology area.


How an Integrated European Hub for Complex Products is unlocking major market opportunities

Pharma Intelligence October 2022

The need for an integrated European developer and manufacturer of complex, differentiated and highly potent products is clearer than ever. Expirations on the patents and/or regulatory...


ONConcept®: An Integrated European Hub for Delivering Highly Potent Complex Products

Pharma Intelligence July 2021

Off-patent, highly potent pharmaceuticals represent a major opportunity. The companies that seize the opportunity will grow sales by delivering products that improve the lives of patients...